NCT02078882View on ClinicalTrials.gov

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis

PHASE4CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions

Primary Biliary Cirrhosis

Interventions

BIOLOGICAL

abatacept

125 mg subcutaneously each week for 24 weeks

Trial Locations (1)

95817

Univeristy of California Davis Medical Center, Sacramento

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Christopher Bowlus, MD

OTHER